UK Markets closed

co.don AG (0Q37.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.5450+0.5746 (+59.21%)
At close: 09:36AM BST

co.don AG

Warthestraße 21
Teltow 14513
49 3328 43 46 0

Full-time employees120

Key executives

NameTitlePayExercisedYear born
Mr. Tilmann BurMember of Exec. Board257kN/A1966
Mr. Matthias MeissnerDirector of Corp. Communications & Investor Relations / PRN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.

Corporate governance

co.don AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.